Stem cell therapy
AMNICELL is the first company to recognize the unique capability of human amniotic
fluid as an abundant source for novel stem cell products
We are passionate about delivering on the promise of amniotic fluid
as an unique source of treatments shaping the future of health
We will deliver new therapies to patients where there are currently few options,
such as serious COVID-19 and other lung disease and non-healing wounds. We will also provide innovative products for hair and skin care, based on regenerative medicine
Stem cell therapy
Stem cells are unspecified cells that are pluripotent, meaning they have the potential to develop into many different cell types in the body. In many tissues, they serve as an internal repair system, dividing essentially without limit to replenish other cells. When stem cells divide, each new cell has the potential to become another type of cell with a more specialized function, such as muscle cells, blood cells, or skin cells. Human amniotic fluid derived stem cells have the potential to be used for important therapies for different diseases, conditions and areas of medical need. Unlike other forms of stem cells, they do not require laboratory manipulation to express these qualities.
Current challenges
AMNICELL uses the unique characteristics of human amniotic fluid derived stem cells to offer a direct line of cells for therapy. Our approach is different from other stem cell companies. Before AMNICELL, scientists primarily worked in laboratories with stem cells from animals and recently from humans. However, human stem cells are usually derived from embryos or from chemically reprogrammed “somatic”, “adult” stem cells, or by transforming adult cells into stem cells using a virus to infect the cell. Those cells are difficult to collect, make in large quantities, and keep viable. They are prone to forming tumors and the potential genetic changes are not fully understood. Other sources of stem cells are not able to form all kinds of new cells with limited lineage capabilities. AMNICELL provides naturally pluripotent stem cells which are not derived from embryos or transformed adult cells.
Future potential
At AMNICELL, we are the first company to collect stem cells and amniotic fluid from the mother at full term pregnancy. This fluid is normally discarded, but we are able to collect this fluid without affecting the mother or child. Our innovative technology enables us to use the amniotic fluid and stem cells for clinical purposes. We are developing therapies for serious COVID 19, pneumonia, ARDS and other lung disease, non-healing wounds, and products for hair and skin care. Other areas of unmet medical needs under consideration are diabetes, pulmonary fibrosis lung disease, arthritis, and neurological diseases.